Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus TRIMETH SULFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus TRIMETH SULFA.
MYTREX F vs TRIMETH/SULFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
Trimethoprim inhibits bacterial dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate; sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking incorporation of para-aminobenzoic acid into folic acid. Sequential blockade of folate synthesis produces synergistic bactericidal effect.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
1 double-strength tablet (160 mg trimethoprim / 800 mg sulfamethoxazole) orally every 12 hours for 14 days.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
Trimethoprim: 8-11 hours; Sulfamethoxazole: 9-11 hours. Prolonged in renal impairment (up to 24-30 hours for both). Clinical context: Dosing interval is typically 12 hours in normal renal function; adjust in CrCl <15-30 mL/min.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Trimethoprim: 50-60% unchanged in urine; Sulfamethoxazole: 15-30% unchanged in urine, with acetylation and glucuronidation metabolites. Approximately 80-90% of dose recovered in urine within 72 hours; remainder via feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic